Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.11)
# 470
Out of 5,127 analysts
511
Total ratings
46.75%
Success rate
14.51%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Reiterates: Buy | $35 | $26.68 | +31.18% | 24 | Feb 10, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $26 → $33 | $27.35 | +20.66% | 23 | Feb 10, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $13 | $4.45 | +192.13% | 30 | Feb 3, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $340 → $1,245 | $320.48 | +288.48% | 31 | Jan 30, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $80 → $117 | $83.88 | +39.48% | 36 | Jan 30, 2026 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $38 | $21.24 | +78.91% | 4 | Jan 9, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 → $0.5 | $0.42 | +18.79% | 19 | Jan 2, 2026 | |
| BHVN Biohaven | Reiterates: Neutral | $11 | $12.20 | -9.84% | 17 | Dec 26, 2025 | |
| RZLT Rezolute | Maintains: Buy | $14 → $5 | $3.07 | +62.87% | 19 | Dec 12, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $34 → $40 | $28.25 | +41.59% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.69 | +610.06% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $20 | $19.40 | +3.09% | 16 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4 | $6.31 | -36.61% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $45 | $22.58 | +99.29% | 27 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $774 → $915 | $833.16 | +9.82% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.60 | +515.38% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $34.72 | +32.49% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.60 | +94.44% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $74.75 | +57.86% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $47.61 | +70.13% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $42.65 | +24.28% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.11 | +231.75% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $30.06 | +13.11% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $26.88 | -29.32% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.99 | +502.01% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.05 | +34,185.71% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.38 | +320.17% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $144.55 | +25.91% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $8.10 | +131.48% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $51.74 | -65.21% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $34.37 | -76.72% | 7 | Jun 11, 2019 |
Immunovant
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $26.68
Upside: +31.18%
Roivant Sciences
Feb 10, 2026
Maintains: Buy
Price Target: $26 → $33
Current: $27.35
Upside: +20.66%
Evolus
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $4.45
Upside: +192.13%
Praxis Precision Medicines
Jan 30, 2026
Maintains: Buy
Price Target: $340 → $1,245
Current: $320.48
Upside: +288.48%
Protagonist Therapeutics
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $83.88
Upside: +39.48%
Pacira BioSciences
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $21.24
Upside: +78.91%
Outlook Therapeutics
Jan 2, 2026
Maintains: Neutral
Price Target: $1 → $0.5
Current: $0.42
Upside: +18.79%
Biohaven
Dec 26, 2025
Reiterates: Neutral
Price Target: $11
Current: $12.20
Upside: -9.84%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.07
Upside: +62.87%
Rapport Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $28.25
Upside: +41.59%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.69
Upside: +610.06%
Nov 11, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $19.40
Upside: +3.09%
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $6.31
Upside: -36.61%
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $22.58
Upside: +99.29%
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $833.16
Upside: +9.82%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.60
Upside: +515.38%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $34.72
Upside: +32.49%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.60
Upside: +94.44%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $74.75
Upside: +57.86%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $47.61
Upside: +70.13%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $42.65
Upside: +24.28%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $2.11
Upside: +231.75%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $30.06
Upside: +13.11%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $26.88
Upside: -29.32%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $2.99
Upside: +502.01%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.05
Upside: +34,185.71%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.38
Upside: +320.17%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $144.55
Upside: +25.91%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $8.10
Upside: +131.48%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $51.74
Upside: -65.21%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $34.37
Upside: -76.72%